In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: AbbVie trades significantly above its PERT-weighted fair value ($294.98 vs. $163.87), indicating potential overvaluation with high downside risk (100% Monte Carlo scenarios below current price). Strong leverage and growth contrast with weak profitability and liquidity scores, highlighting financial strain despite expansion. Valuation dispersion and volatility (37.36% coefficient of variation) suggest elevated investment risk.